Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide for NAFLD in Type 2 Diabetes
NCT03850886Phase 2Completed
- Sponsor
- Ain Shams University
- Start
- Jan 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nicotinamide in non-alcoholic fatty liver disease (NAFLD), sponsored by Ain Shams University. Primary endpoint: Steatosis using Fibroscan with CAP at 3 months. Started Jan 2019; status: completed.
02
Drugs
nicotinamide
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03850886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850886.